We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

EUROIMMUN AG

EUROIMMUN is an international provider of medical laboratory products for autoimmune, infection, allergy and molecula... read more Featured Products: More products

Download Mobile App




Antiphospholipid Antibodies Evaluated in Autoimmune Thyroid Diseases

By LabMedica International staff writers
Posted on 29 Nov 2022
Print article
Image: Antiphospholipid Antibodies Evaluated in Autoimmune Thyroid Diseases (Photo courtesy of VisitHealth limited)
Image: Antiphospholipid Antibodies Evaluated in Autoimmune Thyroid Diseases (Photo courtesy of VisitHealth limited)

Autoimmune thyroid diseases (AITD) is the most common organ-specific autoimmune disease, mainly caused by genetic predisposition, environmental factors and dysfunction in the microbiome.

The main types of AITD are Hashimoto's thyroiditis (HT) and Graves' disease (GD). HT, considered the most common endocrine disorder, is characterized by invasion of the thyroid gland by inflammatory lymphocyte cells. This infiltration induced the destruction and the replacement of follicular tissue leading to hypothyroidism.

Immunologists at the Farhat Hached Hospital (Sousse, Tunisia) carried out a retrospective study that included 195 AITD patients. The inclusion criteria were patients older than 18 years and suffering from HT or GD. Patients with another autoimmune disease associated to AITD were excluded. Sera were consecutively collected between January 2017 and December 2018 from four hospitals in the center of Tunisia. Ninety age-matched healthy blood donors (HBD) served as a control group.

Anti-cardiolipin antibodies (aCL, (IgG, IgA and IgM) were determined by using an enzyme-linked immunosorbent assay (ELISA) (Orgentec Diagnostika, Mainz, Germany). Anti-β2 glycoprotein I antibodies (aβ2GPI, IgG, IgA and IgM) were evaluated by an ELISA (Orgentec Diagnostika) using highly purified human β2GPI. Anti-thyroid peroxidase antibodies (TPO-Ab) and anti-thyroglobulin antibodies (Tg-Ab) were assessed with ELISA kit (Euroimmun, Lübeck, Germany). Human autoantibodies against thyrotropin (TSH) receptor (TRAb) were assessed with an ELISA kit (Euroimmun).

The investigators reported that 154 AITD patients were women and 41 were men. Fifty-six healthy subjects were women and 34 were men. The median age of patients and the control group was 45 and 38.5 years, respectively. The frequency of antiphospholipid (aPL) antibodies was significantly higher in patients with AITD and in patients with HT than in HBD (33.3% versus 11.1%, and 38.1% versus 11.1%). The frequency of aPL in GD was significantly lower than in HT (21.4% versus 38.1%). In patients with HT, aβ2GPI (34.5%) was significantly more frequent than aCL (13.6%). The frequency of aβ2GPI was significantly higher in patients with HT than in healthy population (34.5% versus 11.1%). In HT patients, IgA isotype of aβ2GPI was significantly more common than in healthy blood donors (HBD) and in GD patients (27.3% versus 7.8%, and 27.3% versus 12.5%).

The authors concluded that aβ2GPI and not aCL were frequent in AITD. IgA was the predominant isotype of aβ2GPI and that aβ2GPI-IgA was more frequent in HT than in GD. The study was published on November 25, 2022 in the Journal of Clinical Laboratory Analysis.


Related Links:
Farhat Hached Hospital
Orgentec Diagnostika
Euroimmun

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Signs of multiple sclerosis show up in blood years before symptoms appear (Photo courtesy of vitstudio/Shutterstock)

Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset

Autoimmune diseases such as multiple sclerosis (MS) are thought to occur partly due to unusual immune responses to common infections. Early MS symptoms, including dizziness, spasms, and fatigue, often... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: A new study has identified patterns that predict ovarian cancer relapse (Photo courtesy of Cedars-Sinai)

Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse

High-grade serous ovarian carcinoma is the most lethal type of ovarian cancer, and it poses significant detection challenges. Typically, patients initially respond to surgery and chemotherapy, but the... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.